Windtree Therapeutics Dirección

Dirección controles de criterios 4/4

Windtree Therapeutics' El consejero delegado es Craig Fraser , nombrado en Feb 2016, tiene un mandato de 8.08 años. la remuneración anual total es $940.91K , compuesta por 57.9% salario y 42.1% primas, incluidas acciones y opciones de la empresa. posee directamente 0.12% de las acciones de la empresa, por valor de $3.52K . La antigüedad media del equipo directivo y del consejo de administración es de 3.8 años y 3.1 años respectivamente.

Información clave

Craig Fraser

Chief Executive Officer (CEO)

US$693.6k

Compensación total

Porcentaje del salario del CEO	80.3%
Permanencia del CEO	8.2yrs
Participación del CEO	0.1%
Permanencia media de la dirección	3.9yrs
Promedio de permanencia en la Junta Directiva	3.2yrs

Actualizaciones recientes de la dirección

Recent updates

Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)

Dec 06

Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions

Jul 06

Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable

Jun 09

Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?

Feb 09

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Craig Fraser en comparación con los beneficios de Windtree Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$694k	US$557k	-US$20m
Sep 30 2023	n/a	n/a	-US$25m
Jun 30 2023	n/a	n/a	-US$24m
Mar 31 2023	n/a	n/a	-US$35m
Dec 31 2022	US$941k	US$545k	-US$39m
Sep 30 2022	n/a	n/a	-US$43m
Jun 30 2022	n/a	n/a	-US$47m
Mar 31 2022	n/a	n/a	-US$67m
Dec 31 2021	US$2m	US$480k	-US$68m
Sep 30 2021	n/a	n/a	-US$62m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$35m
Dec 31 2020	US$770k	US$460k	-US$33m
Sep 30 2020	n/a	n/a	-US$32m
Jun 30 2020	n/a	n/a	-US$31m
Mar 31 2020	n/a	n/a	-US$27m
Dec 31 2019	US$1m	US$452k	-US$27m
Sep 30 2019	n/a	n/a	-US$43m
Jun 30 2019	n/a	n/a	-US$40m
Mar 31 2019	n/a	n/a	-US$37m
Dec 31 2018	US$5m	US$437k	-US$35m
Sep 30 2018	n/a	n/a	-US$9m
Jun 30 2018	n/a	n/a	-US$13m
Mar 31 2018	n/a	n/a	-US$17m
Dec 31 2017	US$641k	US$425k	-US$25m

Compensación vs. Mercado: La compensación total ($USD693.63K) de Craig está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD679.77K).

Compensación vs. Ingresos: La compensación de Craig ha sido consistente con los resultados de la empresa en el último año.

CEO

Craig Fraser (58 yo)

8.2yrs

Permanencia

US$693,625

Compensación

Mr. Craig E. Fraser is Chairman of the Board at Windtree Therapeutics, Inc. since June 22, 2023. He has been Chief Executive Officer and President of Windtree Therapeutics, Inc. since February 1, 2016 and...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Craig Fraser	Chairman	8.2yrs	US$693.63k	0.11% $ 3.3k
Eric Curtis	Senior VP & COO	4.1yrs	US$451.73k	0.0040% $ 126.1
Steven Simonson	Senior VP & Chief Medical Officer	9.5yrs	US$491.73k	0.0076% $ 237.5
Jamie McAndrew	VP, Controller	less than a year	sin datos	0.11% $ 3.5k
George Cox	Vice President of Technical Operations	no data	sin datos	sin datos
Pratap Paruchuru	Executive Director of Clinical Development	3.8yrs	sin datos	sin datos
Tracy Rarick	Head of Operations & Program Management	3.8yrs	sin datos	sin datos

3.9yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: WINTEl equipo directivo de la empresa se considera experimentado (3.4 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Craig Fraser	Chairman	8.2yrs	US$693.63k	0.11% $ 3.3k
Daniel Geffken	Independent Director	5yrs	US$65.60k	0.0015% $ 48.3
Mark Strobeck	Independent Director	less than a year	sin datos	sin datos
Leslie Williams	Lead Independent Director	3.2yrs	US$61.85k	0.0011% $ 34.2
Robert Andrew Scott	Independent Director	3.2yrs	US$63.10k	0.0011% $ 34.2

3.2yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de WINT se considera experimentada (3 años de antigüedad promedio).

Windtree Therapeutics Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Windtree Therapeutics, Inc. Appoints Jamie McAndrew as Controller, Chief Accounting Officer and Principal Accounting Officer

Windtree Therapeutics, Inc. Appoints Mark Strobeck to its Board of Directors

Windtree Therapeutics, Inc. Announces Chief Financial Official Officer Changes

Windtree Therapeutics, Inc. Announces Not Stand for Re-Election of Evan Loh from Board

Windtree Therapeutics, Inc., Annual General Meeting, Jun 07, 2022

Independent Chairman of the Board recently bought US$95k worth of stock

Recent updates

Windtree Therapeutics Approves 1-for-18 Reverse Stock Split and Expects Compliance with Listing Requirements of the $1.00 Minimum Bid Price Requirement by The Nasdaq Capital Market

Windtree Therapeutics, Inc. (NasdaqCM:WINT) acquired All of the assets of Varian Biopharmaceuticals, Inc.

Windtree Therapeutics, Inc. announced delayed annual 10-K filing

Windtree Therapeutics Receives Non-Compliance Notice from Nasdaq

New major risk - Revenue and earnings growth

Windtree Therapeutics, Inc. Announces the Start of Patient Dosing in Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.054024 million.

New major risk - Share price stability

Windtree Therapeutics, Inc. Appoints Jamie McAndrew as Controller, Chief Accounting Officer and Principal Accounting Officer

Windtree Therapeutics, Inc. Is Developing A Multi-Asset Franchise of Its Novel Serca2a Activators

Windtree Therapeutics, Inc. Appoints Mark Strobeck to its Board of Directors

Windtree Therapeutics, Inc. Announces Chief Financial Official Officer Changes

Nasdaq Grants Windtree Therapeutics 180-Day Extension to Regain Compliance

Price target decreased to US$3.00

Windtree Therapeutics, Inc. Announces Impairment Charges for the Three Months Ended September 30, 2022

Windtree Therapeutics, Inc. Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (Seismic) Published in the European Journal of Heart Failure

Windtree Therapeutics, Inc. Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America

Windtree Therapeutics, Inc. Reports Impairment for the Second Quarter Ended June 30, 2022

Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value

Windtree Therapeutics Receives Non-Compliance Letter from Nasdaq

Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid

Windtree Therapeutics, Inc. Announces Not Stand for Re-Election of Evan Loh from Board

Windtree Therapeutics, Inc., Annual General Meeting, Jun 07, 2022

Price target decreased to US$5.50

Windtree Therapeutics, Inc. Announces Positive Topline Results from Its Phase 2 Seismic Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics Completes Enrollment in its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome

Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)

Windtree Therapeutics, Inc. Announces Results of U.S. Hospital Claims Data Analysis Showing Hospital Inpatient Mortality and Length of Hospital Stay for Cardiogenic Shock Patients

Independent Chairman of the Board recently bought US$95k worth of stock

Price target decreased to US$8.25

Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions

Independent Non-Executive Director Bruce Peacock has left the company

Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable

Independent Chairman of the Board recently bought US$354k worth of stock

New 90-day low: US$4.94

Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?

Windtree Therapeutics, Inc. Announces Executive Changes

Windtree Appoints Dr. Joseph Soffer to Lead Cardiovascular Clinical Development

Windtree Therapeutics, Inc.(NasdaqCM:WINT) dropped from S&P TMI Index

Windtree Therapeutics, Inc. Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19

New 90-day low: US$4.98

Windtree Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients

Windtree Therapeutics, Inc. Announces FDA Acceptance of IND Application for a Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19

New 90-day low: US$5.94

Earnings released

New 90-day high - US$9.90

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad